Sign in
Taking people in United StatesPhase 2

Tests stem cell transplant with cell removal in young people with blood disorders

Tests removing certain immune cells from donor stem cells in young people.

Key facts

Who runs it
Mitchell Cairo
Where
Valhalla, United StatesSee the site
Trial code
Registry title
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
1 Apr 2021
Expected to end
31 Dec 2027
Type of study
Interventional
Treatments tested
  • alpha beta depletion
Record updated
23 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teens and young adults up to 30 years old who need a stem cell transplant from a donor for certain blood cancers or non-cancer blood diseases.

Age
0 to 30 years (from 1 day old up to 30 years)
Sex
All sexes can join.
Disease stage
High-risk acute leukemia (ALL or AML), including after treatment failure or relapse; high-risk myelodysplastic syndrome; Hodgkin or non-Hodgkin lymphoma that did not respond or came back; Kostmann syndrome, Diamond-Blackfan anemia or amegakaryocytic thrombocytopenia; sickle cell disease.
Earlier treatment
Kostmann syndrome: no response to, or cannot take, granulocyte colony-stimulating factor. Diamond-Blackfan anemia: no response to, or cannot take, corticosteroids and/or cyclosporine. Cannot have had a donor stem cell transplant within the last 6 months, unless it is a boost.
Biomarker or test result
Some leukemia types are asked for by a chromosome or gene change, for example t(9;22), 11q23, hypodiploidy or FLT3 mutation, or by leftover leukemia cells (MRD) after treatment.

Main reasons for not taking part

  • Pregnant or breast-feeding women cannot join.
  • Uncontrolled infection at the time of entry.
  • Karnofsky/Lansky performance score below 60.
  • Shown lack of compliance with medical care.
  • Donor stem cell transplant within 6 months, unless it is a boost.

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • ALL:ALL high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (<15% blasts at time of registration), mixed phenotype acute leukemia (MPAL), persistent MRD (<0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (44 chromosomes)) in first remission ' ALL in second remission and beyond
  • AML: History of AML induction/reinduction Failure (<15% blasts at time of registration); AML in CR1 with poor cytogenetics (i.e. 12p, 5a, -7, FLT3 mutation/duplication, t(9;11) and others); AML with persistent minimal residual disease (MRD) in CR1(<0.01% on flow or persistent abnormal karyotype detected by cytogenetics); AML CR2 or beyond; AML in refractory relapse but ≤15% bone marrow leukemia blasts; Therapy-related AML
  • High Risk Myelodysplastic syndrome (MDS) 4 Lymphoma: Hodgkin (HL) or Non-Hodgkin (NHL): HL or NHL in induction failure; HL or NHL in PR1 or PR2 ; HL or NHL in CR2 or subsequent remission
  • Bone marrow failure syndromes: Kostmann syndrome refractory or intolerant to granulocyte colony-33stimulating factor; Diamond-Blackfan anemia refractory or intolerant to corticosteroids and/or cyclosporine'; amegakaryocytic thrombocytopenia 6. Sickle Cell Disease (Homozygous Hemoglobin S Disease, or Hemoglobin S β 0/+ thalassemia, or Hemoglobin SC Disease) 7. age 0-30 years 8. adequate organ function

Who cannot take part

  • Patients who have received allogeneic HSCT within 6 months, unless being done as a boost
  • Patients with documented uncontrolled infection at the time of study entry are not eligible
  • Karnofsky/Lansky (age appropriate) Performance Score <60
  • Females who are pregnant or breast-feeding are not eligible
  • Demonstrated lack of compliance with medical care
  • Patients with active <Grade 2 GVHD

Where in United States

  • New York Medical CollegeValhalla, United StatesContact: Mitchell S Cairo, MDTaking people

About the trial

What the trial wants to find out

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

The group in the trial

  • alpha beta cell depletionTreatment being tested

    Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.

    Treatment: alpha beta depletion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588
Plain-language title
Tests stem cell transplant with cell removal in young people with blood disordersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 October 2026